ELGX - Endologix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.51
-0.03 (-1.18%)
At close: 4:00PM EDT

2.51 0.00 (0.00%)
After hours: 5:02PM EDT

Stock chart is not supported by your current browser
Previous Close2.54
Open2.63
Bid2.46 x 2200
Ask2.53 x 1000
Day's Range2.50 - 2.64
52 Week Range2.35 - 6.72
Volume560,855
Avg. Volume561,075
Market Cap212.615M
Beta-0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.56
Trade prices are not sourced from all markets
  • Business Wire6 days ago

    Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

    Endologix, Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffrey S. Brown as the Company’s Chief Operations Officer, effective as of August 13, 2018. John Onopchenko, Chief Executive Officer of Endologix, Inc., said, “I am very excited to have someone with Jeff’s credentials and industry knowledge joining our executive team.

  • Here's Why Endologix Plummeted 37% Today
    Motley Fool11 days ago

    Here's Why Endologix Plummeted 37% Today

    Earnings guidance isn't what it used to be.

  • Endologix (ELGX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks12 days ago

    Endologix (ELGX) Reports Q2 Loss, Tops Revenue Estimates

    Endologix (ELGX) delivered earnings and revenue surprises of 5.26% and 0.88%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Endologix: 2Q Earnings Snapshot

    The Irvine, California-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs, came to 18 cents per share. The results beat Wall Street expectations. The average ...

  • Business Wire12 days ago

    Endologix Reports Second Quarter 2018 Financial Results

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018.

  • ACCESSWIRE12 days ago

    Endologix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Endologix, Inc. (NASDAQ: ELGX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern Time. To ...

  • 3 Dental Stocks to Top Earnings Estimates This Season
    Zacks21 days ago

    3 Dental Stocks to Top Earnings Estimates This Season

    On upbeat consumer sentiment and increased business investments, the dental supplies industry appears to be in the pink of health now.

  • ACCESSWIRE21 days ago

    Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Valeritas Holdings Inc. (NASDAQ: VLRX).

  • Business Wirelast month

    Endologix, Inc. to Announce Second Quarter 2018 Financial Results on August 9, 2018

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2018 after the market close on Thursday, August 9, 2018. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com.

  • ACCESSWIRE2 months ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Endologix, Sanmina, First American Financial, Expeditors International of Washington, Liberty Broadband, and Nu Skin Enterprises — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Endologix, ...

  • Business Wire2 months ago

    Endologix Reports Positive 1-Year Results from the Ovation® LUCY Study

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, announced 1-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) registry as reported on Saturday, June 23rd at the 2018 Society for Vascular Surgery Annual Meeting. The LUCY study is a prospective, consecutively enrolling, non-randomized, multi-center, post-market registry evaluating the Ovation System for the endovascular treatment of abdominal aortic aneurysms (AAA) in women.3 The study enrolled a total of 225 patients, including 76 females in the treatment group and 149 males in the control group, at 39 sites in the U.S. The primary endpoint of the study was the 30-day Major Adverse Event ("MAE") rate and secondary endpoints including serious and non-serious adverse events through one year.

  • Business Wire2 months ago

    Endologix Appoints Jeffry Fecho as Chief Quality Officer

    Endologix, Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffry Fecho as the Company’s Chief Quality Officer, effective as of June 25, 2018 (the “Effective Date”). John Onopchenko, Chief Executive Officer of Endologix, Inc., said, “I’m very pleased to welcome Jeff to our executive team. Mr. Fecho brings to Endologix almost thirty years of executive leadership and quality expertise.

  • What Is Endologix Inc’s (NASDAQ:ELGX) Share Price Doing?
    Simply Wall St.2 months ago

    What Is Endologix Inc’s (NASDAQ:ELGX) Share Price Doing?

    Endologix Inc (NASDAQ:ELGX), a medical equipment company based in United States, led the NasdaqGS gainers with a relatively large price hike in the past couple of weeks. With many analystsRead More...

  • ACCESSWIRE3 months ago

    Free Daily Technical Summary Reports on Endologix and Three Other Medical Supplies Stocks

    Ahead of today's trading session, WallStEquities.com scans Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Halyard Health Inc. (NYSE: HYH). Companies in the Medical Instruments and Supplies space manufacture and sell medical devices, instrument systems, and reagents and consumables.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ELGX earnings conference call or presentation 2-May-18 8:30pm GMT

    Q1 2018 Endologix Inc Earnings Call

  • Associated Press4 months ago

    Endologix: 1Q Earnings Snapshot

    The Irvine, California-based company said it had a loss of 24 cents per share. Losses, adjusted for non-recurring costs and to extinguish debt, were 16 cents per share. The results beat Wall Street expectations. ...

  • Business Wire4 months ago

    Endologix Appoints John Onopchenko as Chief Executive Officer

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company’s Chief Executive Officer, effective immediately. Dan Lemaitre, Chairman of the Board of Directors of Endologix, Inc., commented, “We are very pleased to welcome John as our Chief Executive Officer. Over the course of the past seven months in the COO role, John has shown the Board first hand that he is an exceptional operator with significant manufacturing, clinical, and regulatory experience.

  • Business Wire4 months ago

    Endologix Reports First Quarter 2018 Financial Results

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2018.

  • Business Wire4 months ago

    Endovascular Aneurysm Sealing (EVAS) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair (EVAR) in New Study

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced the results of a study, which was presented by Marc Schermerhorn, M.D., Chief of Vascular Surgery at Beth Israel Deaconess Medical Center, on the podium at the Late-Breaking Aortic Trials Session during the Charing Cross 40th International Symposium.

  • Has Endologix Inc (NASDAQ:ELGX) Improved Earnings Growth In Recent Times?
    Simply Wall St.4 months ago

    Has Endologix Inc (NASDAQ:ELGX) Improved Earnings Growth In Recent Times?

    Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Endologix Inc’s (NASDAQ:ELGX) track record on a highRead More...

  • Business Wire5 months ago

    Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018

    Endologix, Inc.  , a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2018 after the market close on Wednesday, May 2, 2018.

  • Business Wire5 months ago

    Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair using Ovation® Abdominal Stent Graft Systems.

  • Will Endologix Inc’s (NASDAQ:ELGX) Earnings Grow In The Year Ahead?
    Simply Wall St.5 months ago

    Will Endologix Inc’s (NASDAQ:ELGX) Earnings Grow In The Year Ahead?

    Looking at Endologix Inc’s (NASDAQ:ELGX) earnings update in December 2017, analyst consensus outlook appear pessimistic, with profits predicted to drop by -15.79% next year. Though this is still an improvementRead More...